Low 17-Hydroxyprogesterone (17-OHP) Levels
A low 17-OHP level in pregnancy may indicate corpus luteum dysfunction and has been associated with spontaneous abortion and ectopic pregnancy, though single measurements are not diagnostic. In non-pregnant contexts, low 17-OHP is normal in healthy adults and children, while markedly elevated levels indicate congenital adrenal hyperplasia.
Clinical Context and Interpretation
In Pregnancy
Low 17-OHP levels in early pregnancy have been associated with corpus luteum failure and may contribute to spontaneous abortion, with aborters showing lower 17-OHP levels compared to women with viable pregnancies 1.
Single measurements of 17-OHP are not diagnostic for ectopic pregnancy, as levels overlap significantly (50%) with intrauterine pregnancies, though mean levels are significantly lower only at 6-7 weeks gestation 2.
The relationship between low 17-OHP and pregnancy loss suggests corpus luteum defect may be primary, though no minimal threshold has been established for salvaging intrauterine pregnancies 2.
In Non-Pregnant Adults and Children
Normal 17-OHP levels in healthy men average 0.094 μg/100 mL, with 90% originating from Leydig cells 3.
Normal values for children are less than 1.1 μg/L (less than 3.3 nmol/L) 4.
17-OHP exhibits marked circadian variation, with evening values (8 PM) being only 40% of morning values (8 AM) 3.
Evaluation Approach
When to Suspect Pathology
Markedly elevated (not low) 17-OHP levels indicate disease, specifically:
Congenital adrenal hyperplasia (CAH) presents with 17-OHP levels 50-200 times normal in affected children 3.
Values up to several hundred μg/L are found in untreated CAH (21-hydroxylase deficiency) 4.
Diagnostic Testing
In bilateral adrenal incidentalomas, measure serum 17-OHP to exclude congenital adrenal hyperplasia 5.
Newborn screening cutoff values should be adjusted for preterm infants, low birth weight, and sick newborns, as 17-OHP concentration shows significant negative correlation with birth weight (r=-0.488) and gestational age (r=-0.560) 6.
Blood sampling is preferred over 24-hour urine collection for diagnostic convenience 4.
Management Considerations
Progesterone Supplementation Context
While historical studies suggested progesterone replacement when 17-OHP levels drop below normal in early pregnancy 1, current evidence does not support routine progesterone supplementation based solely on low 17-OHP levels.
Important regulatory update: The FDA withdrew approval of 17-alpha hydroxyprogesterone caproate (17-OHPC) in April 2023 due to lack of evidence for preventing recurrent preterm birth 7.
Current Recommendations for Preterm Birth Prevention
For singleton pregnancies with prior spontaneous preterm birth: No longer recommend 17-OHPC; consider shared decision-making regarding vaginal progesterone 7.
For singleton pregnancies without prior preterm birth but with short cervix (≤20 mm at ≤24 weeks): Vaginal progesterone (90-mg gel or 200-mg suppository daily) remains indicated 5.
Common Pitfalls
Do not use single 17-OHP measurements to diagnose ectopic pregnancy - levels overlap significantly with intrauterine pregnancies 2.
Account for circadian variation when interpreting 17-OHP levels - morning values are significantly higher than evening values 3.
Adjust reference ranges for preterm and low birth weight newborns to avoid false-positive CAH screening results 6.
Do not prescribe 17-OHPC for preterm birth prevention - FDA approval has been withdrawn due to lack of efficacy 7.